title: [Epidermolysis bullosa acquisita and hepatitis C].
abstract: BACKGROUND
  Epidermolysis bullosa acquisita is a bullous dermatosis. Its etiology remains unknown and the efficacy of its treatment is low.
  
  
  METHODS
  We report the first association between epidermolysis bullosa acquisita, chronic hepatitis C and cryoglobulinemia, healing with interferon alpha and ribavirine.
  
  
  CONCLUSIONS
  We suggest a role for hepatitis C virus in the pathogenesis of epidermolysis bullosa acquisita. We suppose a synthesis of autoimmune antibodies in a dysimmune environment. Interferon alpha and ribavirine might be a new therapeutic avenue but further studies are necessary to confirm it.
authors.affiliation: Clinique Dermatologique, Hôpital Edouard Herriot, Lyon.
authors.forename: S
authors.initials: S
authors.lastname: Thiery
authors.forename: L
authors.initials: L
authors.lastname: Misery
authors.forename: P
authors.initials: P
authors.lastname: Chossegros
authors.forename: J
authors.initials: J
authors.lastname: Kanitakis
authors.forename: R
authors.initials: R
authors.lastname: Ghohestani
authors.forename: J Y
authors.initials: JY
authors.lastname: Forestier
authors.forename: C
authors.initials: C
authors.lastname: Trepo
authors.forename: M
authors.initials: M
authors.lastname: Faure
authors.forename: A
authors.initials: A
authors.lastname: Claudy
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016107:Epidermolysis Bullosa Acquisita / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin